Enrollment Completed for Low-Risk Aortic and Mitral Patient Groups For On-X Life Technologies, Inc.® Prosthetic Heart Valve Anticoagulation Clinical Study
5/7/2013 11:18:54 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
MINNEAPOLIS--(BUSINESS WIRE)--On-X® Life Technologies, Inc. (On-X LTI) announced today that enrollment for the Low-Risk Aortic Valve and Mitral Valve Patient Groups has been completed. The Prospective Randomized On-X Valve Anticoagulation Trial (PROACT) was initiated with US FDA approval in 2006 and is being conducted at 36 centers throughout the United States and Canada. The purpose of the Low-Risk Patient Group of the PROACT trial is to determine if qualified recipients of the On-X aortic heart valve can be safely maintained with aspirin and clopidogrel (Plavix®). The announcement was made today at the American Association for Thoracic Surgery (AATS) annual meeting.
Help employers find you! Check out all the jobs and post your resume.
comments powered by